Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.
Price History & Performance
|Historical stock prices|
|Current Share Price||USh94.00|
|52 Week High||USh85.00|
|52 Week Low||USh105.00|
|1 Month Change||3.75%|
|3 Month Change||-6.00%|
|1 Year Change||-6.93%|
|3 Year Change||-63.99%|
|5 Year Change||n/a|
|Change since IPO||-64.12%|
Recent News & Updates
|CQCIL||UG Pharmaceuticals||UG Market|
Return vs Industry: CQCIL underperformed the UG Pharmaceuticals industry which returned 87.5% over the past year.
Return vs Market: CQCIL underperformed the UG Market which returned -0.1% over the past year.
Stable Share Price: CQCIL is not significantly more volatile than the rest of UG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: CQCIL's weekly volatility (2%) has been stable over the past year.
About the Company
Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. It offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine and Tenofovir; and Dolutegravir, Lamivudine and Tenofovir tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of of Hepatitis B infection.
Cipla Quality Chemical Industries Fundamentals Summary
|CQCIL fundamental statistics|
Is CQCIL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CQCIL income statement (TTM)|
|Cost of Revenue||USh229.51b|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.89|
|Net Profit Margin||-3.70%|
How did CQCIL perform over the long term?See historical performance and comparison
Is Cipla Quality Chemical Industries undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CQCIL (UGX94) is trading above our estimate of fair value (UGX44.71)
Significantly Below Fair Value: CQCIL is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CQCIL is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.
PE vs Market: CQCIL is unprofitable, so we can't compare its PE Ratio to the UG market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CQCIL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CQCIL is overvalued based on its PB Ratio (2.5x) compared to the XF Pharmaceuticals industry average (1.6x).
How is Cipla Quality Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cipla Quality Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cipla Quality Chemical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CQCIL is currently unprofitable.
Growing Profit Margin: CQCIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CQCIL is unprofitable, and losses have increased over the past 5 years at a rate of 63.5% per year.
Accelerating Growth: Unable to compare CQCIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CQCIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).
Return on Equity
High ROE: CQCIL has a negative Return on Equity (-7.77%), as it is currently unprofitable.
How is Cipla Quality Chemical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its short term liabilities (UGX65.8B).
Long Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its long term liabilities (UGX24.7B).
Debt to Equity History and Analysis
Debt Level: CQCIL's debt to equity ratio (25.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CQCIL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CQCIL's debt is well covered by operating cash flow (79.5%).
Interest Coverage: CQCIL's interest payments on its debt are not well covered by EBIT (1.5x coverage).
What is Cipla Quality Chemical Industries's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CQCIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CQCIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CQCIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CQCIL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CQCIL is not paying a notable dividend for the UG market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CQCIL's dividend in 3 years as they are not forecast to pay a notable one for the UG market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nevin Bradford (64 yo)
Mr. Nevin J. Bradford has been the Chief Executive Officer and Executive Director of Cipla Quality Chemical Industries Limited since November 26, 2013. Mr. Bradford serves as an Executive Director and Head...
Experienced Management: CQCIL's management team is seasoned and experienced (10.3 years average tenure).
Experienced Board: CQCIL's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cipla Quality Chemical Industries Limited's employee growth, exchange listings and data sources
- Name: Cipla Quality Chemical Industries Limited
- Ticker: CQCIL
- Exchange: UGSE
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: USh343.279b
- Shares outstanding: 3.65b
- Website: https://www.ciplaqcil.co.ug
Number of Employees
- Cipla Quality Chemical Industries Limited
- Luzira Industrial Park
- Plot 1-7, 1st Ring Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 16:00|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.